{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:08:30Z","timestamp":1792667310645,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005187","name":"University of Athens","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Due to their key role in the pathogenesis of cancer through the regulation of apoptosis, the B-cell leukemia\/lymphoma-2 (BCL-2) family proteins have been an attractive target for cancer therapy for the past decades. Throughout the years, many Bcl-2 family inhibitors have been developed, with Venetoclax being now successfully used in treating hematological malignancies. Although their effectiveness in the treatment of solid tumors is yet to be established, some preclinical evidence indicates their possible clinical application. This review aims to summarize current data from completed clinical trials that used Bcl-2 protein family inhibitors as monotherapy or in combination with other agents for the treatment of solid malignancies. We managed to include clinical trials of various phases which analyze the pharmacokinetics and pharmacodynamics of the drugs, as well as the effectiveness and adverse effects. Active and recruiting clinical trials are also briefly presented and future prospects and challenges are discussed.<\/jats:p>","DOI":"10.1007\/s12094-022-03070-9","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T12:05:03Z","timestamp":1673611503000},"page":"1554-1578","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Bcl-2 pathway inhibition in solid tumors: a review of clinical trials"],"prefix":"10.1007","volume":"25","author":[{"given":"Ioanna","family":"Ploumaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthymios","family":"Triantafyllou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1156-7139","authenticated-orcid":false,"given":"Ioannis-Alexios","family":"Koumprentziotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Karampinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Drougkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Karavolias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Trontzas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias A.","family":"Kotteas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"3070_CR1","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nm1087","volume":"10","author":"B Vogelstein","year":"2004","unstructured":"Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789\u201399. https:\/\/doi.org\/10.1038\/nm1087.","journal-title":"Nat Med"},{"key":"3070_CR2","doi-asserted-by":"publisher","first-page":"21087","DOI":"10.3390\/ijms141021087","volume":"14","author":"S Sarkar","year":"2013","unstructured":"Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S, et al. Cancer development, progression, and therapy: an epigenetic overview. Int J Mol Sci. 2013;14:21087\u2013113. https:\/\/doi.org\/10.3390\/ijms141021087.","journal-title":"Int J Mol Sci"},{"key":"3070_CR3","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/35037734","volume":"407","author":"P Meier","year":"2000","unstructured":"Meier P, Finch A, Evan G. Apoptosis in development. Nature. 2000;407:796\u2013801. https:\/\/doi.org\/10.1038\/35037734.","journal-title":"Nature"},{"key":"3070_CR4","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/35037710","volume":"407","author":"MO Hengartner","year":"2000","unstructured":"Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407:770\u20136. https:\/\/doi.org\/10.1038\/35037710.","journal-title":"Nature"},{"key":"3070_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/cdd.2017.183","volume":"25","author":"J Montero","year":"2018","unstructured":"Montero J, Letai A. Why do BCL-2 inhibitors work and where should we use them in the clinic? Cell Death Differ. 2018;25:56\u201364. https:\/\/doi.org\/10.1038\/cdd.2017.183.","journal-title":"Cell Death Differ"},{"key":"3070_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/ppo.0000000000000408","volume":"25","author":"CE Ryan","year":"2019","unstructured":"Ryan CE, Davids MS. BCL-2 inhibitors, present and future. Cancer J. 2019;25:401\u20139. https:\/\/doi.org\/10.1097\/ppo.0000000000000408.","journal-title":"Cancer J"},{"key":"3070_CR7","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/348334a0","volume":"348","author":"D Hockenbery","year":"1990","unstructured":"Hockenbery D, Nu\u00f1ez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990;348:334\u20136. https:\/\/doi.org\/10.1038\/348334a0.","journal-title":"Nature"},{"key":"3070_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/cdd.2017.189","volume":"25","author":"F Pentimalli","year":"2018","unstructured":"Pentimalli F. BCL2: a 30-year tale of life, death and much more to come. Cell Death Differ. 2018;25:7\u20139. https:\/\/doi.org\/10.1038\/cdd.2017.189.","journal-title":"Cell Death Differ"},{"key":"3070_CR9","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/cancers13061292","volume":"13","author":"S Hafezi","year":"2021","unstructured":"Hafezi S, Rahmani M. Targeting BCL-2 in cancer: advances, challenges, and perspectives. Cancers (Basel). 2021;13:1292. https:\/\/doi.org\/10.3390\/cancers13061292.","journal-title":"Cancers (Basel)"},{"key":"3070_CR10","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","volume":"127","author":"MA Anderson","year":"2016","unstructured":"Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016;127:3215\u201324. https:\/\/doi.org\/10.1182\/blood-2016-01-688796.","journal-title":"Blood"},{"key":"3070_CR11","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1053\/sonc.2003.50041","volume":"30","author":"SR Frankel","year":"2003","unstructured":"Frankel SR. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom\u2019s macroglobulinemia: a targeted approach to enhance apoptosis. Semin Oncol. 2003;30:300\u20134. https:\/\/doi.org\/10.1053\/sonc.2003.50041.","journal-title":"Semin Oncol"},{"key":"3070_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1089\/108729002760220798","volume":"12","author":"RJ Klasa","year":"2002","unstructured":"Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 2002;12:193\u2013213. https:\/\/doi.org\/10.1089\/108729002760220798.","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"3070_CR13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/s0046-8177(97)90129-5","volume":"28","author":"T Nakamura","year":"1997","unstructured":"Nakamura T, Nomura S, Sakai T, Nariya S. Expression of bcl-2 oncoprotein in gastrointestinal and uterine carcinomas and their premalignant lesions. Hum Pathol. 1997;28:309\u201315. https:\/\/doi.org\/10.1016\/s0046-8177(97)90129-5.","journal-title":"Hum Pathol"},{"key":"3070_CR14","first-page":"2571","volume":"17","author":"KE Valassiadou","year":"1997","unstructured":"Valassiadou KE, Stefanaki K, Tzardi M, Datseris G, Georgoulias V, Melissas J, et al. Immunohistochemical expression of p53, bcl-2, mdm2 and waf1\/p21 proteins in colorectal adenocarcinomas. Anticancer Res. 1997;17:2571\u20136.","journal-title":"Anticancer Res"},{"key":"3070_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/(sici)1096-9896(199611)180:3%3C259::aid-path654%3E3.0.co;2-1","volume":"180","author":"J Mueller","year":"1996","unstructured":"Mueller J, Mueller E, Hoepner I, J\u00fctting J, Bethke B, Stolte M, et al. Expression of bcl-2 and p53 in de novo and ex-adenoma colon carcinoma: a comparative immunohistochemical study. J Pathol. 1996;180:259\u201365. https:\/\/doi.org\/10.1002\/(sici)1096-9896(199611)180:3%3C259::aid-path654%3E3.0.co;2-1.","journal-title":"J Pathol"},{"key":"3070_CR16","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/annonc\/mdj067","volume":"17","author":"MM Mita","year":"2006","unstructured":"Mita MM, Ochoa L, Rowinsky EK, Kuhn J, Schwartz G, Hammond LA, et al. A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense\u2122, G3139) and irinotecan in patients with metastatic colorectal cancer. Ann Oncol. 2006;17:313\u201321. https:\/\/doi.org\/10.1093\/annonc\/mdj067.","journal-title":"Ann Oncol"},{"key":"3070_CR17","doi-asserted-by":"publisher","unstructured":"Oblimersen. Drugs in R & D. 2007;8:321\u201334. https:\/\/doi.org\/10.2165\/00126839-200708050-00006","DOI":"10.2165\/00126839-200708050-00006"},{"key":"3070_CR18","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1200\/jco.2006.06.0483","volume":"24","author":"AY Bedikian","year":"2006","unstructured":"Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the oblimersen melanoma study group. J Clin Oncol. 2006;24:4738\u201345. https:\/\/doi.org\/10.1200\/jco.2006.06.0483.","journal-title":"J Clin Oncol"},{"key":"3070_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/s0090-4295(99)00453-7","volume":"54","author":"ME Gleave","year":"1999","unstructured":"Gleave ME, Miayake H, Goldie J, Nelson C, Tolcher A. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. Urology. 1999;54:36\u201346. https:\/\/doi.org\/10.1016\/s0090-4295(99)00453-7.","journal-title":"Urology"},{"key":"3070_CR20","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1634\/theoncologist.7-4-360","volume":"7","author":"S Goodin","year":"2002","unstructured":"Goodin S, Rao Kv, DiPaola RS. State-of-the-art treatment of metastatic hormone-refractory prostate cancer. Oncologist. 2002;7:360\u201370. https:\/\/doi.org\/10.1634\/theoncologist.7-4-360.","journal-title":"Oncologist"},{"key":"3070_CR21","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1093\/annonc\/mdn784","volume":"20","author":"CN Sternberg","year":"2009","unstructured":"Sternberg CN, Dumez H, van Poppel H, Skoneczna I, Sella A, Daugaard G, et al. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol. 2009;20:1264\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdn784.","journal-title":"Ann Oncol"},{"key":"3070_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/943648","volume":"2014","author":"M Vogler","year":"2014","unstructured":"Vogler M. Targeting BCL2-proteins for the treatment of solid tumours. Adv Med. 2014;2014:1\u201314. https:\/\/doi.org\/10.1155\/2014\/943648.","journal-title":"Adv Med"},{"key":"3070_CR23","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/jco.2010.31.6208","volume":"29","author":"L Gandhi","year":"2011","unstructured":"Gandhi L, Camidge DR, de Oliveira MR, Bonomi P, Gandara D, Khaira D, et al. Phase I Study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011;29:909\u201316. https:\/\/doi.org\/10.1200\/jco.2010.31.6208.","journal-title":"J Clin Oncol"},{"key":"3070_CR24","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/cncr.20907","volume":"103","author":"HK Berrieman","year":"2005","unstructured":"Berrieman HK, Smith L, O\u2019Kane SL, Campbell A, Lind MJ, Cawkwell L. The expression of Bcl-2 family proteins differs between nonsmall cell lung carcinoma subtypes. Cancer. 2005;103:1415\u20139. https:\/\/doi.org\/10.1002\/cncr.20907.","journal-title":"Cancer"},{"key":"3070_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/jto.0000000000000027","volume":"9","author":"A Chiappori","year":"2014","unstructured":"Chiappori A, Williams C, Northfelt DW, Adams JW, Malik S, Edelman MJ, et al. Obatoclax mesylate, a Pan\u2013Bcl-2 inhibitor, in combination with docetaxel in a phase 1\/2 trial in relapsed non\u2013small-cell lung cancer. J Thorac Oncol. 2014;9:121\u20135. https:\/\/doi.org\/10.1097\/jto.0000000000000027.","journal-title":"J Thorac Oncol"},{"key":"3070_CR26","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.lungcan.2011.05.005","volume":"74","author":"PK Paik","year":"2011","unstructured":"Paik PK, Rudin CM, Pietanza MC, Brown A, Rizvi NA, Takebe N, et al. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer. 2011;74:481\u20135. https:\/\/doi.org\/10.1016\/j.lungcan.2011.05.005.","journal-title":"Lung Cancer"},{"key":"3070_CR27","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.lungcan.2014.05.003","volume":"85","author":"CJ Langer","year":"2014","unstructured":"Langer CJ, Albert I, Ross HJ, Kovacs P, Blakely LJ, Pajkos G, et al. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer. Lung Cancer. 2014;85:420\u20138. https:\/\/doi.org\/10.1016\/j.lungcan.2014.05.003.","journal-title":"Lung Cancer"},{"key":"3070_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.564108","author":"NN Mohamad Anuar","year":"2020","unstructured":"Mohamad Anuar NN, Nor Hisam NS, Liew SL, Ugusman A. Clinical review: navitoclax as a pro-apoptotic and anti-fibrotic agent. Front Pharmacol. 2020. https:\/\/doi.org\/10.3389\/fphar.2020.564108.","journal-title":"Front Pharmacol"},{"key":"3070_CR29","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1158\/1078-0432.ccr-11-3090","volume":"18","author":"CM Rudin","year":"2012","unstructured":"Rudin CM, Hann CL, Garon EB, de Oliveira MR, Bonomi PD, Camidge DR, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012;18:3163\u20139. https:\/\/doi.org\/10.1158\/1078-0432.ccr-11-3090.","journal-title":"Clin Cancer Res"},{"key":"3070_CR30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ygyno.2022.01.021","volume":"165","author":"F Joly","year":"2022","unstructured":"Joly F, Fabbro M, Follana P, Lequesne J, Medioni J, Lesoin A, et al. A phase II study of navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: the MONAVI\u2014GINECO study. Gynecol Oncol. 2022;165:30\u20139. https:\/\/doi.org\/10.1016\/j.ygyno.2022.01.021.","journal-title":"Gynecol Oncol"},{"key":"3070_CR31","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1158\/1078-0432.ccr-20-4084","volume":"27","author":"EM Bertino","year":"2021","unstructured":"Bertino EM, Gentzler RD, Clifford S, Kolesar J, Muzikansky A, Haura EB, et al. Phase IB study of osimertinib in combination with navitoclax in EGFR -mutant NSCLC following resistance to initial EGFR therapy (ETCTN 9903). Clin Cancer Res. 2021;27:1604\u201311. https:\/\/doi.org\/10.1158\/1078-0432.ccr-20-4084.","journal-title":"Clin Cancer Res"},{"key":"3070_CR32","doi-asserted-by":"publisher","first-page":"e1721","DOI":"10.1038\/cddis.2015.97","volume":"6","author":"MA Debrincat","year":"2015","unstructured":"Debrincat MA, Pleines I, Lebois M, Lane RM, Holmes ML, Corbin J, et al. BCL-2 is dispensable for thrombopoiesis and platelet survival. Cell Death Dis. 2015;6:e1721\u2013e1721. https:\/\/doi.org\/10.1038\/cddis.2015.97.","journal-title":"Cell Death Dis"},{"key":"3070_CR33","doi-asserted-by":"publisher","first-page":"100798","DOI":"10.1016\/j.neo.2022.100798","volume":"29","author":"W Yao","year":"2022","unstructured":"Yao W, Bai L, Wang S, Zhai Y, Sun S-Y. Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2\/Bcl-XL dual inhibitor that induces Bax-dependent apoptosis. Neoplasia. 2022;29:100798. https:\/\/doi.org\/10.1016\/j.neo.2022.100798.","journal-title":"Neoplasia"},{"key":"3070_CR34","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1200\/JCO.2020.38.15_suppl.3509","volume":"38","author":"NJ Lakhani","year":"2020","unstructured":"Lakhani NJ, Rasco DW, Zeng Q, Tang Y, Liang Z, Wang H, et al. First-in-human study of palcitoclax (APG-1252), a novel dual Bcl-2\/Bcl-xL inhibitor, demonstrated advantages in platelet safety while maintaining anticancer effect in US patients with metastatic solid tumors. J Clin Oncol. 2020;38:3509\u20133509.","journal-title":"J Clin Oncol"},{"key":"3070_CR35","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/ph15020144","volume":"15","author":"O Renner","year":"2022","unstructured":"Renner O, Mayer M, Leischner C, Burkard M, Berger A, Lauer UM, et al. Systematic review of gossypol\/AT-101 in cancer clinical trials. Pharmaceuticals. 2022;15:144. https:\/\/doi.org\/10.3390\/ph15020144.","journal-title":"Pharmaceuticals"},{"key":"3070_CR36","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1620\/tjem.138.275","volume":"138","author":"H Hoshiai","year":"1982","unstructured":"Hoshiai H, Uehara S, Mori R, Nagaike F, Tsuiki A, Suzuki M. Gossypol as oral contraceptive for male: trial case report. Tohoku J Exp Med. 1982;138:275\u201380. https:\/\/doi.org\/10.1620\/tjem.138.275.","journal-title":"Tohoku J Exp Med"},{"key":"3070_CR37","doi-asserted-by":"publisher","first-page":"5922","DOI":"10.1038\/s41598-021-84970-8","volume":"11","author":"H Cao","year":"2021","unstructured":"Cao H, Sethumadhavan K, Cao F, Wang TTY. Gossypol decreased cell viability and down-regulated the expression of a number of genes in human colon cancer cells. Sci Rep. 2021;11:5922. https:\/\/doi.org\/10.1038\/s41598-021-84970-8.","journal-title":"Sci Rep"},{"key":"3070_CR38","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.2174\/0929867324666170523123655","volume":"26","author":"Y Zeng","year":"2019","unstructured":"Zeng Y, Ma J, Xu L, Wu D. Natural product gossypol and its derivatives in precision cancer medicine. Curr Med Chem. 2019;26:1849\u201373. https:\/\/doi.org\/10.2174\/0929867324666170523123655.","journal-title":"Curr Med Chem"},{"key":"3070_CR39","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1158\/1535-7163.mct-10-0936","volume":"10","author":"X Pang","year":"2011","unstructured":"Pang X, Wu Y, Wu Y, Lu B, Chen J, Wang J, et al. (\u2212)-Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signaling-mediated angiogenesis. Mol Cancer Ther. 2011;10:795\u2013805. https:\/\/doi.org\/10.1158\/1535-7163.mct-10-0936.","journal-title":"Mol Cancer Ther"},{"key":"3070_CR40","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s62963","author":"D Wang","year":"2014","unstructured":"Wang D, Li M, Sui J, Ren T, Li Z, Zhang L, et al. Identification of a novel potential antitumor activity of gossypol as an APE1\/Ref-1 inhibitor. Drug Des Devel Ther. 2014. https:\/\/doi.org\/10.2147\/dddt.s62963.","journal-title":"Drug Des Devel Ther"},{"key":"3070_CR41","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/jto.0b013e31820a0ea6","volume":"6","author":"N Ready","year":"2011","unstructured":"Ready N, Karaseva NA, Orlov Sv, Luft Av, Popovych O, Holmlund JT, et al. Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. J Thorac Oncol. 2011;6:781\u20135. https:\/\/doi.org\/10.1097\/jto.0b013e31820a0ea6.","journal-title":"J Thorac Oncol"},{"key":"3070_CR42","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/annonc\/mdr555","volume":"23","author":"G Sonpavde","year":"2012","unstructured":"Sonpavde G, Matveev V, Burke JM, Caton JR, Fleming MT, Hutson TE, et al. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol. 2012;23:1803\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdr555.","journal-title":"Ann Oncol"},{"key":"3070_CR43","doi-asserted-by":"publisher","first-page":"6066","DOI":"10.1200\/JCO.2019.37.15_suppl.6066","volume":"37","author":"P Swiecicki","year":"2019","unstructured":"Swiecicki P, Bellile E, Casper K, Malloy KM, Kupfer R, Spector ME, et al. A randomized trial of laryngeal organ preservation evaluating two cycles of induction chemotherapy with platinum, docetaxel, and a novel Bcl-xL inhibitor. J Clin Oncol. 2019;37:6066\u20136066.","journal-title":"J Clin Oncol"},{"key":"3070_CR44","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1136\/gutjnl-2020-321175","volume":"70","author":"S Song","year":"2021","unstructured":"Song S, Chen Q, Li Y, Lei G, Scott A, Huo L, et al. Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma. Gut. 2021;70:2238\u201348. https:\/\/doi.org\/10.1136\/gutjnl-2020-321175.","journal-title":"Gut"},{"key":"3070_CR45","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","volume":"76","author":"ED Deeks","year":"2016","unstructured":"Deeks ED. Venetoclax: first global approval. Drugs. 2016;76:979\u201387. https:\/\/doi.org\/10.1007\/s40265-016-0596-x.","journal-title":"Drugs"},{"key":"3070_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.212574","volume":"8","author":"LM Ju\u00e1rez-Salcedo","year":"2019","unstructured":"Ju\u00e1rez-Salcedo LM, Desai V, Dalia S. Venetoclax: evidence to date and clinical potential. Drugs Context. 2019;8:1\u201313. https:\/\/doi.org\/10.7573\/dic.212574.","journal-title":"Drugs Context"},{"key":"3070_CR47","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1200\/JCO.2021.39.15_suppl.1004","volume":"39","author":"GJ Lindeman","year":"2021","unstructured":"Lindeman GJ, Bowen R, Jerzak KJ, Song X, Decker T, Boyle FM, et al. Results from VERONICA: a randomized, phase II study of second-\/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA\/MBC). J Clin Oncol. 2021;39:1004\u20131004.","journal-title":"J Clin Oncol"},{"key":"3070_CR48","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1158\/1078-0432.ccr-21-3811","volume":"28","author":"GJ Lindeman","year":"2022","unstructured":"Lindeman GJ, Fernando TM, Bowen R, Jerzak KJ, Song X, Decker T, et al. VERONICA: randomized phase II study of fulvestrant and venetoclax in ER-Positive metastatic breast cancer post-CDK4\/6 inhibitors\u2014efficacy, safety, and biomarker results. Clin Cancer Res. 2022;28:3256\u201367. https:\/\/doi.org\/10.1158\/1078-0432.ccr-21-3811.","journal-title":"Clin Cancer Res"},{"key":"3070_CR49","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2021-151852","volume":"138","author":"J Ravikrishnan","year":"2021","unstructured":"Ravikrishnan J, Muhowski EM, Lai T-H, Misra S, Diaz Rohena D, Tan F, et al. Characterization of LP-118, a novel small molecule inhibitor of Bcl-2 and Bcl-Xl in chronic lymphocytic leukemia resistant to venetoclax. Blood. 2021;138:679\u2013679. https:\/\/doi.org\/10.1182\/blood-2021-151852.","journal-title":"Blood"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-022-03070-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-022-03070-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-022-03070-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T05:38:27Z","timestamp":1684733907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-022-03070-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["3070"],"URL":"https:\/\/doi.org\/10.1007\/s12094-022-03070-9","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"assertion":[{"value":"6 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there are no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals  performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}